AAM, PhRMA Renew Rivalry In Hatch-Waxman Public Comments

Generic association advocates enforcement action against companies that use REMS to block generics while PhRMA disputes claims of REMS abuse and citizen petition delay tactics.

More from Generics

More from Biosimilars & Generics